Protocol and rationale: a 24-week double-blind, randomized, placebo controlled trial of the efficacy of adjunctive garcinia mangostanaLinn. (mangosteen) pericarp for schizophrenia

Turner, Alyna, McGrath, John J., Dean, Olivia M., Dodd, Seetal, Baker, Andrea, Cotton, Susan M., Scott, James G., Kavanagh, Bianca E., Ashton, Melanie M., Walker, Adam J., Brown, Ellie and Berk, Michael 2019, Protocol and rationale: a 24-week double-blind, randomized, placebo controlled trial of the efficacy of adjunctive garcinia mangostanaLinn. (mangosteen) pericarp for schizophrenia, Clinical psychopharmacology and neuroscience, vol. 17, no. 2, pp. 297-307, doi: 10.9758/cpn.2019.17.2.297.

Attached Files
Name Description MIMEType Size Downloads

Title Protocol and rationale: a 24-week double-blind, randomized, placebo controlled trial of the efficacy of adjunctive garcinia mangostanaLinn. (mangosteen) pericarp for schizophrenia
Author(s) Turner, AlynaORCID iD for Turner, Alyna orcid.org/0000-0001-7389-2546
McGrath, John J.
Dean, Olivia M.ORCID iD for Dean, Olivia M. orcid.org/0000-0002-2776-3935
Dodd, SeetalORCID iD for Dodd, Seetal orcid.org/0000-0002-7918-4636
Baker, Andrea
Cotton, Susan M.
Scott, James G.
Kavanagh, Bianca E.
Ashton, Melanie M.ORCID iD for Ashton, Melanie M. orcid.org/0000-0001-6832-4157
Walker, Adam J.ORCID iD for Walker, Adam J. orcid.org/0000-0002-5399-1245
Brown, Ellie
Berk, MichaelORCID iD for Berk, Michael orcid.org/0000-0002-5554-6946
Journal name Clinical psychopharmacology and neuroscience
Volume number 17
Issue number 2
Start page 297
End page 307
Total pages 11
Publisher Korean College of Neuropsychopharmacology
Place of publication Seoul, South Korea
Publication date 2019-05-31
ISSN 1738-1088
Keyword(s) Garcinia mangostana Linn.
Mangosteen
Oxidative stress
Psychotic disorder
Schizophrenia
Treatment clinical trial
Science & Technology
Life Sciences & Biomedicine
Neurosciences
Pharmacology & Pharmacy
Neurosciences & Neurology
SYNDROME SCALE PANSS
BIPOLAR DISORDER
DEPRESSION
SYMPTOMS
ULTRASTRUCTURE
QUESTIONNAIRE
NEUROGENESIS
METAANALYSIS
HALOPERIDOL
Summary Objective: : Garcinia mangostana Linn., commonly known as mangosteen, is a tropical fruit with a thick pericarp rind containing bioactive compounds that may be beneficial as an adjunctive treatment for schizophrenia. The biological underpinnings of schizophrenia are believed to involve altered neurotransmission, inflammation, redox systems, mitochondrial dysfunction, and neurogenesis. Mangosteen pericarp contains xanthones which may target these biological pathways and improve symptoms; this is supported by preclinical evidence. Here we outline the protocol for a double- blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp (1,000 mg/day), compared to placebo, in the treatment of schizophrenia. Methods: : We aim to recruit 150 participants across two sites (Geelong and Brisbane). Participants diagnosed with schizophrenia or schizoaffective disorder will be randomized to receive 24 weeks of either adjunctive 1,000 mg/day of mangosteen pericarp or matched placebo, in addition to their usual treatment. The primary outcome measure is mean change in the Positive and Negative Symptom Scale (total score) over the 24 weeks. Secondary outcomes include positive and negative symptoms, general psychopathology, clinical global severity and improvement, depressive symptoms, life satisfaction, functioning, participants reported overall improvement, substance use, cognition, safety and biological data. A 4-week post treatment interview at week 28 will explore post-discontinuations effects. Results: : Ethical and governance approvals were gained and the trial commenced. Conclusion: : A positive finding in this study has the potential to provide a new adjunctive treatment option for people with schizophrenia and schizoaffective disorder. It may also lead to a greater understanding of the pathophysiology of the disorder.
Language eng
DOI 10.9758/cpn.2019.17.2.297
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2019, The Korean College of Neuropsychopharmacology
Persistent URL http://hdl.handle.net/10536/DRO/DU:30120655

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Checking
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 86 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Thu, 11 Apr 2019, 15:13:42 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.